CGA and neoplasm: Chromogranin A (CgA) has replaced the 24-h urine collection of 5-hydroxyindoleacetic acid and has become the most important tumour marker in the monitoring of NET during and after treatment and is recommended by the European NeuroEndocrine Tumor Society (Korse et al, 2009; O'Toole et al, 2009).